Personalizing colistin dosage for preterm neonates
Official title: Colistin in Neonatal ICU Patients With Gram Negative Resistant Infection: Dosage Personalization Approach
Run by Helwan University · NCT06472271 · Data updated 2026-11-12
This study is testing whether a higher dose of colistin can safely treat serious infections in preterm babies better than a lower dose while trying to avoid kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 0 Days to 28 Days |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Helwan University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | July 30, 2024 |
| Main results expected | November 30, 2024 |
| Study ends | October 30, 2025 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT06472271 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include critically ill neonates aged 0-30 days, born before 37 weeks, with nosocomial infections caused by culture-resistant gram-negative bacteria.
✕Probably not a fit
Patients with pre-existing renal impairment or those receiving concurrent nephrotoxic medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to determine the optimal intravenous colistin dosing strategies for treating multidrug-resistant gram-negative infections in preterm neonates. It will compare the safety and efficacy of a conventional low dose of 5 mg/kg/day versus a higher dose of 7.5 mg/kg/day. The study will involve a retrospective analysis followed by a prospective design to assess pharmacokinetics and identify factors influencing acute kidney injury (AKI) incidence. The goal is to improve colistin exposure while minimizing nephrotoxicity risks.
Why it matters
Potential benefit: If successful, this study could lead to safer and more effective colistin dosing strategies for vulnerable preterm neonates.
How similar studies have gone: Previous studies have shown promising results with higher colistin doses in adults, but this specific approach in neonates is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Neonates aged between (0-30 days) born before 37 weeks * Critically ill patients with nosocomial infection with proven culture-resistant gram-negative bacteria. * Neonates who are indicated for colistin and started colistin therapy for at least 48 hr. Exclusion Criteria: * Serum creatinine ≥1.5 baseline before colistin * Received colistin before NICU stay * Administration of concurrent nephrotoxic drugs including amphotericin, gentamicin, or amikacin. * Major congenital anomalies or with previous renal impairment.
Where it's running
-
Cairo univrsity Hospitals
Cairo, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Managing staghorn kidney stones with retrograde intrarenal surgery
This tests whether a new bendable, suction-enabled ureteral access sheath works better than a standard sheath during retrograde intrarenal surgery for adults with staghorn kidney stones.
-
Evaluating the heart protection of dapagliflozin in breast cancer patients undergoing chemotherapy
This study is testing if the medication dapagliflozin can help protect the hearts of breast cancer patients from damage while they receive chemotherapy.
-
New method to close holes in the nasal septum
This study is testing a new type of nasal mesh to see if it can help close holes in the nasal septum for people who need surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.